Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News

Pharma News

Astellas Drops Duchenne Muscular Dystrophy Gene Therapies and Other Studies

Astellas Drops Duchenne Muscular Dystrophy Gene Therapies and Other Studies

Astellas Pharma said it will end three gene therapy programs for the treatment of patients with Duchenne muscular dystrophy (DMD) based on disappointing preclinical data, along with several other p...

Vitamin-D, Omega-3, exercise can reduce cancer risk by 61%: StudyVitamin-D, Omega-3, exercise can reduce cancer risk by 61%: Study

Vitamin-D, Omega-3, exercise can reduce cancer risk by 61%: StudyVitamin-D, Omega-3, exercise can reduce cancer risk by 61%: Study

A combination of high-dose Vitamin D, Omega-3s, and simple home strength exercises can help reduce cancer risk in healthy adults aged 70 or older by 61 per cent, claims a study. ...

Catalent snaps up NJ cell therapy plant for $44.5M days after revealing big biologics expansion

Catalent snaps up NJ cell therapy plant for $44.5M days after revealing big biologics expansion

Days after throwing down $350 million to beef up biologics manufacturing in Indiana, high-flying CDMO Catalent is buying a cell therapy plant on the East Coast. ...

FDA grants fast track designation to CMG901 for gastrointestinal cancers

FDA grants fast track designation to CMG901 for gastrointestinal cancers

The FDA granted fast track designation to CMG901 for treatment of certain patients with gastrointestinal cancers.

Landmark DNA study finds 58 new mutations that cause cancer

Landmark DNA study finds 58 new mutations that cause cancer

A massive study has analyzed the genomes of cancer cells from more than 12,000 patients, identifying 58 new mutational signatures that offer clues to novel causes of cancer. ...

Study Reveals Inappropriate Antibiotic Prescription Practices

Study Reveals Inappropriate Antibiotic Prescription Practices

Almost three-quarters of antibiotic prescriptions to patients aged 65 years or older and two-thirds to Black patients are inappropriate, according to a U.S. study of more than 7 billion visits to d...

Arcturus’ COVID-19 Vaccine Phase 3 Study Shows Promising Results

Arcturus’ COVID-19 Vaccine Phase 3 Study Shows Promising Results

San Diego, Calif.-based Arcturus Therapeutics said that its messenger RNA (mRNA) vaccine has demonstrated strong protection against COVID-19 in a large late-stage study. ...

Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)

Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)

Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people's health and the quality of patients' lives, today announced that the U.S. Food and Drug Admini...

Axsome agrees to post-marketing commitments with FDA, signaling potential OK for long-delayed depression drug

Axsome agrees to post-marketing commitments with FDA, signaling potential OK for long-delayed depression drug

Axsome Therapeutics is likely on the cusp of its first drug approval, sending shares of its stock up more than 40% pre-market on Tuesday.

Enzyvant to build regenerative medicine manufacturing plant

Enzyvant to build regenerative medicine manufacturing plant

Enzyvant, which focuses on developing regenerative medicines for rare diseases, has laid out plans to build a new manufacturing facility in the Research Triangle Park area of North Carolina. ...

$FDA Grants Fast Track Designation to ADI-001 in Relapsed/Refractory Non-Hodgkin Lymphoma$

FDA Grants Fast Track Designation to ADI-001 in Relapsed/Refractory Non-Hodgkin Lymphoma

The FDA has granted a fast track designation to the CAR T-cell therapy ADI-001 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma. ...

AbbVie Pulls Plug on Parkinson’s Partnership With BioArctic

AbbVie Pulls Plug on Parkinson’s Partnership With BioArctic

AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson's disease and other movement disorders. ...

158 159 160 161162163 164 165 166